retatrutide mechanism triple agonist gip glp-1 glucagon receptor Beyond GLP- 1: Retatrutide's triple-agonist (GLP-1, GIP, glucagon) is redefining metabolic health. Phase 2 data shows ~24% weight loss—surpassing semaglutide & tirzepatide. Evidence-based 💉 A triple-action once-weekly injection

To date, investigations into the effects of cruciferous vegetables and their glucosinolates have largely focused on hyperglycemia and diabetes, hypertension, and dyslipidemia

The Brazilian market for GLP-1 agonists, which includes semaglutide, is estimated at around US$1.8 billion

Why should patients have to feel sick to their stomachs for the privilege of having their disease treated

The current study Study author Yuya Koide and his colleagues wanted to explore how individuals with type 2 diabetes respond to GLP-1RAs therapy (Koide et al., 2025)

Implications for Plan Sponsors The Newkirk lawsuit illustrates the legal and operational risks of relying on vague exclusions or failing to update plan documents in response to evolving medical standards

Its most common signs include a slight yellow tinge to the whites of the eyes and skin